Cargando…
Carbon footprint of industry-sponsored late-stage clinical trials
OBJECTIVES: To quantify the carbon footprint from a sample of pharma industry sponsored phase III trials. To develop an approach that can readily be applied to future trials by AstraZeneca and other trial sponsors. DESIGN: Life cycle assessment including all the sources of carbon emissions associate...
Autores principales: | Mackillop, Neil, Shah, Jayesh, Collins, Michael, Costelloe, Thomas, Öhman, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445340/ https://www.ncbi.nlm.nih.gov/pubmed/37604634 http://dx.doi.org/10.1136/bmjopen-2023-072491 |
Ejemplares similares
-
The Environmental footprint of morphine: a life cycle assessment from opium poppy farming to the packaged drug
por: McAlister, Scott, et al.
Publicado: (2016) -
Health impacts and environmental footprints of diets that meet the Eatwell Guide recommendations: analyses of multiple UK studies
por: Scheelbeek, Pauline, et al.
Publicado: (2020) -
Drivers of malnutrition among late adolescent and young women in rural Pakistan: a cross-sectional assessment of the MaPPS trial
por: Baxter, Jo-Anna B, et al.
Publicado: (2023) -
The Costs of Industry-Sponsored Drug Trials in Canada
por: Tran, Dat T., et al.
Publicado: (2019) -
Differential Globalization of Industry- and Non-Industry–Sponsored Clinical Trials
por: Atal, Ignacio, et al.
Publicado: (2015)